Bristol-Myers Squibb (BRM) Stock Forecast & Price Target

19 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BRM Analyst Ratings

Moderate Buy

8 Buy

11 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BRM Stock 12 Month Forecast

Average Price Target

€58.77

▲(1.78% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is €58.77 with a high forecast of €71.69 and a low forecast of €34.97. The average price target represents a 1.78% change from the last price of €57.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"€33","72":"€72","42.75":"€42.8","52.5":"€52.5","62.25":"€62.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":71.68521426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€71.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.76633418333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.9683972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,42.75,52.5,62.25,72],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.74,58.81270878923077,59.88541757846154,60.95812636769231,62.030835156923075,63.10354394615385,64.17625273538461,65.24896152461538,66.32167031384616,67.39437910307691,68.46708789230769,69.53979668153846,70.61250547076922,{"y":71.68521426,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.74,57.81894878333333,57.89789756666667,57.97684635,58.05579513333334,58.13474391666667,58.2136927,58.29264148333334,58.37159026666667,58.45053905,58.52948783333334,58.60843661666667,58.68738540000001,{"y":58.76633418333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.74,55.988338246153845,54.236676492307694,52.48501473846154,50.73335298461539,48.98169123076923,47.23002947692308,45.47836772307692,43.72670596923077,41.975044215384614,40.22338246153846,38.471720707692306,36.72005895384615,{"y":34.9683972,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.565,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.756,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.648,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.989,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.491,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.019,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.459,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.793,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.879,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.656,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.099,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.74,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€71.69

Average Price Target€58.77

Lowest Price Target€34.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

RBC Capital

€55.95

Hold

-3.10%

Downside

Reiterated

09/21/26

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

€65.57→€71.69

Buy

24.15%

Upside

Reiterated

09/16/26

Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler

Rajesh Kumar

HSBC

€52.45→€56.82

Hold

-1.59%

Downside

Reiterated

09/10/26

Bristol Myers price target raised to $65 from $60 at HSBCBristol Myers price target raised to $65 from $60 at HSBC

Evan Seigerman

BMO Capital

€52.45

Hold

-9.16%

Downside

Reiterated

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Stryker (NYSE: SYK) and InnovAge Holding (NASDAQ: INNV)

Louise Chen

Scotiabank

€52.45

Hold

-9.16%

Downside

Reiterated

09/09/26

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Revolution Medicines (NASDAQ: RVMD) and MDxHealth (NASDAQ: MDXH)

Michael Yee

UBS

€69.94

Buy

21.12%

Upside

Reiterated

08/20/26

Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target

Geoff Meacham

Citi

€61.19

Hold

5.98%

Upside

Reiterated

08/14/26

Citi Remains a Hold on Bristol-Myers Squibb (BMY)

Terence Flynn

Morgan Stanley

€34.97

Sell

-39.44%

Downside

Reiterated

08/14/26

Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/14/26

Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data

Emily Field

Barclays

€65.57

Buy

13.55%

Upside

Reiterated

08/11/26

Barclays Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

Chris Schott

J.P. Morgan

€63.82

Buy

10.53%

Upside

Reiterated

08/04/26

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. Morgan

Jasper Hellweg

Argus Research

€65.57

Buy

13.55%

Upside

Upgraded

08/04/26

Bristol Myers upgraded to Buy from Hold at ArgusBristol Myers upgraded to Buy from Hold at Argus

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€52.45→€56.82

Hold

-1.59%

Downside

Reiterated

08/03/26

Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)

Jason Gerberry

Bank of America Securities

€62.07

Buy

7.50%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Alignment Healthcare (ALHC), Bristol-Myers Squibb (BMY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

RBC Capital

€55.95

Hold

-3.10%

Downside

Reiterated

09/21/26

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

€65.57→€71.69

Buy

24.15%

Upside

Reiterated

09/16/26

Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler

Rajesh Kumar

HSBC

€52.45→€56.82

Hold

-1.59%

Downside

Reiterated

09/10/26

Bristol Myers price target raised to $65 from $60 at HSBCBristol Myers price target raised to $65 from $60 at HSBC

Evan Seigerman

BMO Capital

€52.45

Hold

-9.16%

Downside

Reiterated

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Stryker (NYSE: SYK) and InnovAge Holding (NASDAQ: INNV)

Louise Chen

Scotiabank

€52.45

Hold

-9.16%

Downside

Reiterated

09/09/26

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Revolution Medicines (NASDAQ: RVMD) and MDxHealth (NASDAQ: MDXH)

Michael Yee

UBS

€69.94

Buy

21.12%

Upside

Reiterated

08/20/26

Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target

Geoff Meacham

Citi

€61.19

Hold

5.98%

Upside

Reiterated

08/14/26

Citi Remains a Hold on Bristol-Myers Squibb (BMY)

Terence Flynn

Morgan Stanley

€34.97

Sell

-39.44%

Downside

Reiterated

08/14/26

Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/14/26

Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data

Emily Field

Barclays

€65.57

Buy

13.55%

Upside

Reiterated

08/11/26

Barclays Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

Chris Schott

J.P. Morgan

€63.82

Buy

10.53%

Upside

Reiterated

08/04/26

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. Morgan

Jasper Hellweg

Argus Research

€65.57

Buy

13.55%

Upside

Upgraded

08/04/26

Bristol Myers upgraded to Buy from Hold at ArgusBristol Myers upgraded to Buy from Hold at Argus

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€52.45→€56.82

Hold

-1.59%

Downside

Reiterated

08/03/26

Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)

Jason Gerberry

Bank of America Securities

€62.07

Buy

7.50%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Alignment Healthcare (ALHC), Bristol-Myers Squibb (BMY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

MDWDMediwound

OCULOcular Therapeutix

GHGuardant Health

HROWHarrow Health

DNLIDenali Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months

Srikripa DevarakondaTruist Financial

Success Rate

12/16 ratings generated profit

Average Return

+9.56%

Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +9.56% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

16/19 ratings generated profit

Average Return

+15.53%

Copying David Risinger's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +15.53% per trade.

2 Years

David RisingerLeerink Partners

Success Rate

18/19 ratings generated profit

Average Return

+19.66%

Copying David Risinger's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +19.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRM Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BRM has received 16 Buy Ratings, 31 Hold Ratings, and 2 Sell Ratings. BRM average Analyst price target in the past 3 months is 58.77.

Each month's total comprises the sum of three months' worth of ratings.

BRM Financial Forecast

BRM Earnings Forecast

Next quarter’s earnings estimate for BRM is €1.51 with a range of €1.39 to €1.68. The previous quarter’s EPS was €1.78. BRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BRM has Performed in-line its overall industry.

BRM Sales Forecast

Next quarter’s sales forecast for BRM is €11.03B with a range of €10.43B to €11.42B. The previous quarter’s sales results were €11.35B. BRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BRM has Performed in-line its overall industry.

BRM Stock Forecast FAQ

What is DE:BRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 58.77.

What is DE:BRM’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb has 1.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bristol-Myers Squibb a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s share price target?

The average share price target for Bristol-Myers Squibb is 58.77. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €71.69 ,and the lowest forecast is €34.97. The average share price target represents 1.78% Increase from the current price of €57.74.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Bristol-Myers Squibb?

To buy shares of DE:BRM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bristol-Myers Squibb (BRM) Stock Forecast & Price Target

BRM Analyst Ratings

BRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BRM Analyst Recommendation Trends

BRM Financial Forecast

BRM Earnings Forecast

BRM Sales Forecast

BRM Stock Forecast FAQ

Detailed List of Analyst Forecasts